DrugPatentWatch Database Preview

Luxembourg Supplementary Protection Certificates

« Back to Dashboard

Supplementary Protection Certificates

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

Country	Patent Number	Supplementary Protection Certificate	SPC Country	SPC Description	SPC Expiration
European Patent Office	1300396	92113	Luxembourg	PRODUCT NAME: PERAMPANEL ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (FYCOMPA)
European Patent Office	2187879	LUC00017	Luxembourg	PRODUCT NAME: GLYXAMBI- EMPAGLIFLOZINE/LINAGLIPTINE; AUTHORISATION NUMBER AND DATE: EU/1/16/1146 20161115
European Patent Office	1786785	92155	Luxembourg	PRODUCT NAME: CRIZOTINIB, EVENTUELLEMENT SOUS LA FORME D UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE
European Patent Office	2727918	LUC00102	Luxembourg	PRODUCT NAME: BRAFTOVI - ENCORAFENIB; MEKTOVI - BINIMETINIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1314 20180924
European Patent Office	1532149	91889	Luxembourg	91889, EXPIRES: 20260824
European Patent Office	1973545	92327	Luxembourg	PRODUCT NAME: PONATINIB SOUS TOUTES SES FORMES TELLES QUE PROTEGEES PAR LE BREVET DE BASE
European Patent Office	1415987	92858	Luxembourg	PRODUCT NAME: LENVATINIB, OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES OU UN HYDRATE DE CELUI-CI